


Supplementary Table S1: Current clinical trials addressing some components affecting EOC immunogenicity

Clinical trial ID	Phase	Line	Treatment	Diseases treated	References
NCT01112293	II	Relapsed	Anti-TGF Monoclonal Antibody (GC1008)	Pleural Malignant Mesothelioma	[222]
NCT04935359	III	First line	NIS793 in Combination with Gemcitabine and Nab-paclitaxel	Metastatic PDAC	[223]
NCT05145569	I	Metastatic	Neoadjuvant Chemotherapy (Carboplatin AUC 5 and paclitaxel) With or Without BINTRAFUSP ALFA (M7824)	Metastatic Advanced OC	NA
NCT02538471	II	Metastatic	LY2157299 Monohydrate (LY2157299) and Radiotherapy	Metastatic Breast Cancer	[224]
NCT04429542	I	First line	Bifunctional EGFR/TGF β Fusion Protein BCA101 Monotherapy and in Combination Therapy	EGFR-Driven Advanced Solid Tumors (HNSCC, SCCL, cSCC, SCC EOC, PC)	[200,225]
NCT00063401	II	First line	Cetuximab (C225)/Paclitaxel/Carboplatin	Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	NA
NCT02954523	I/II	First line	Dasatinib and Osimertinib (AZD9291)	Advanced NSCLC With EGFR Mutations	[201]
NCT04511871	I	Relapsed/refractory	CAR modified autologous T cells (CCT303-406)	HER2 Positive Solid Tumors	Study still enrolling
NCT04562298	I	Relapsed/refractory	CAR-T cell therapy (LCAR-M23) targeting MSLN	EOC	NA
NCT02580747	I	Relapsed/Chemo refractory	Patient autologous or donor-derived T cells transduced with the anti-meso vector (CART-meso cells)	Advanced Malignancies: malignant mesothelioma, OC, PC, TNBC, EC, and other mesothelin positive tumors	NA
NCT01583686	I/II	Metastatic	Lymphodepleting conditioning followed by infusion of anti-mesothelin gene engineered T lymphocytes	Metastatic or unresectable cancer expressing mesothelin	NA
NCT05211557	I	Relapsed	Fully Human B7H3 (CD276) CAR-T cells	Recurrent Malignant OC	Study still enrolling
NCT05472857	I	Advanced	CLDN18.2-targeting CAR T Cells	Solid tumors with positive CLDN18.2 expression (GC, PC, OC, gastroesophageal junction adenocarcinoma)	Study still enrolling
NCT05225363	I	Platinum resistant	TAG72-CAR T Cells	Platinum Resistant EOC	Study still enrolling

NCT05613088	II	Platinum resistant	Farletuzumab ecteribulin (MORAb-202, Folate Receptor Alpha-targeting Antibody-drug Conjugate) compared to investigator choice of chemotherapy	HGSC, primary peritoneal, or fallopian tube cancer	Study still enrolling
NCT04300556	I/II	Platinum resistant	Farletuzumab Ecteribulin	OC, endometrial cancer, NSCLC, TNBC	Study still enrolling
NCT02671435	I/II	Metastatic	Durvalumab (MEDI4736) and Monalizumab	Advanced solid tumors	NA
NCT05769959	I/II	Metastatic	Study of RO7515629	Advanced or metastatic solid tumors expressing HLA-G (RCC, NSCLC, pancreatic adenocarcinoma, CC, ovarian neoplasms)	Study still enrolling
NCT00529022	I	Platinum resistant	Azacitidine and Valproic Acid Plus Carboplatin	Platinum Resistant EOC	NA
NCT02900560	II	Platinum resistant/refractory	Pembrolizumab With or Without oral azacitidine (CC-486)	EOC	NA

Abbreviations: Pancreatic ductal adenocarcinoma [PDAC], ovarian cancer [OC], epithelial ovarian cancer [EOC], head and neck squamous cell carcinoma [HNSCC], squamous cell carcinoma of the lung [SCCL], cutaneous squamous cell carcinoma [cSCC], squamous cell carcinoma [SCC], pancreatic cancer [PC], endometrial cancer [EC], high-grade serous ovarian cancer [HGSC], non-small cell lung carcinoma [NSCLC], gastric cancer [GC], triple-negative breast cancer [TNBC]), renal adenocarcinoma [RCC], colorectal cancer [CC], NA: No publications available.



Supplementary Figure S1. Average gene expression of HLA I allotypes increases in correlation with the average EMT gene expression in ovarian cancer cells. Gene expression of HLA I allotypes in ovarian cancer cells.